Core Viewpoint - The company, Xintiandi (301277.SZ), has stated that it currently does not have any intermediate pharmaceutical products for antiviral flu treatment, but is progressing with its research products, including Oseltamivir phosphate raw materials and Oseltamivir phosphate capsules, as planned [1]. Group 1 - The company has no antiviral flu intermediate pharmaceutical products available at this time [1] - The research products in the antiviral flu field include Oseltamivir phosphate raw materials and Oseltamivir phosphate capsules [1] - The development of these products is proceeding according to schedule [1]

Core Viewpoint - The company, Xintiandi (301277.SZ), has stated that it currently does not have any intermediate pharmaceutical products for antiviral flu treatment, but is progressing with its research products, including Oseltamivir phosphate raw materials and Oseltamivir phosphate capsules, as planned [1] Group 1 - The company has no antiviral flu intermediate pharmaceutical products available at this time [1] - The research products in the antiviral flu field include Oseltamivir phosphate raw materials and Oseltamivir phosphate capsules [1] - The development of these products is proceeding according to schedule [1]